Caribou Biosciences Appoints Biotechnology Industry Veteran Ran Zheng to its Board of Directors
September 29 2021 - 4:05PM
Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage
CRISPR genome-editing biopharmaceutical company, announced today it
has appointed Ran Zheng to its board of directors. Ms. Zheng brings
over 25 years of biotechnology industry leadership experience in
biologics drug development with broad expertise in technical
operations and the manufacture of gene and cell therapies.
“It is my pleasure to welcome Ran to our board of directors,”
said Rachel Haurwitz, Ph.D., Caribou’s president and chief
executive officer. “Ran brings a wealth of strategic and
operational expertise in the development of gene and cell
therapies, from engineering and process development through
manufacturing and supply chain management. We look forward to
benefitting from her perspective and experience as we advance our
chRDNA-edited allogeneic CAR-T and CAR-NK cell therapies for the
potential treatment of challenging hematologic malignancies and
solid tumors.”
“Caribou has developed an innovative and differentiated
genome-editing technology that enables a pipeline of off-the-shelf
allogeneic cell therapies designed to increase persistence and
anti-tumor activity,” said Ms. Zheng. “The work Caribou is doing to
develop allogeneic cell therapies has the potential to make a real
difference in the lives of patients with serious diseases. Caribou
is clearly a leader in this field, and I am excited to join its
board of directors.”
Ms. Zheng currently serves as chief executive officer and on the
board of directors of Landmark Bio, a public benefit limited
liability company that was formed to advance the development of
transformative new medicines by translating today’s cutting-edge
research into tomorrow’s breakthrough therapies. Landmark Bio
focuses on the emerging technologies of cell and gene therapies,
mRNA, and other novel modalities to enable and accelerate drug
development and biomedical innovation. Prior to joining Landmark
Bio earlier this year, Ms. Zheng most recently served as chief
technical officer at Orchard Therapeutics, a commercial-stage
global gene therapy company specializing in hematopoietic stem
cell-based gene therapies. In that role, Ms. Zheng led the
technical operations organization and helped advance the company’s
product pipeline, including contributing to the approval of
Libmeldy® therapy in Europe, the first gene therapy product for
metachromatic leukodystrophy. Ms. Zheng has also held leadership
positions at multiple biotechnology companies including Genzyme
(now Sanofi) and Amgen. At Amgen, Ms. Zheng held positions of
increasing responsibility in process development, clinical and
commercial manufacturing, as well as supply chain, and played a key
role in building differentiated capabilities in manufacturing for
clinical supply and commercial product launch to enable speed to
clinic and speed to market strategies for Amgen’s innovative
products. Ms. Zheng received an M.S. in microbial engineering from
the University of Minnesota and a B.S. in biology from Beijing
Forestry University.
About Caribou’s Novel Next-Generation CRISPR
PlatformCRISPR genome editing uses easily designed,
modular biological tools to make DNA changes in living cells. There
are two basic components of Type II CRISPR systems: the nuclease
protein that cuts DNA and the RNA molecule(s) that guide the
nuclease to generate a site-specific, double-stranded break,
leading to an edit at the targeted genomic site. CRISPR systems
occasionally edit unintended genomic sites, known as off-target
editing, which may lead to harmful effects on cellular function and
phenotype. In response to this challenge, Caribou has developed
chRDNAs (pronounced “chardonnays”), RNA-DNA hybrid guides that
direct substantially more precise genome editing compared to
all-RNA guides. Caribou is deploying the power of the chRDNA
technology to carry out high efficiency multiple edits, including
multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc.Caribou is a
clinical-stage CRISPR genome-editing biopharmaceutical company
dedicated to transforming the lives of patients with devastating
diseases by applying the company’s proprietary chRDNA technology
toward the development of next-generation, genome-edited cell
therapies. The company is developing a pipeline of genome-edited,
off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of
both hematologic malignancies and solid tumors against cell surface
targets for which autologous CAR-T cell therapeutics have
previously demonstrated clinical proof of concept, as well as
additional emerging targets.
Forward-Looking StatementsThis press release
contains forward-looking statements, within the meaning of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, without limitation, statements
related to Caribou’s pipeline of cell therapies, potential
treatments, and expectations regarding its business. Management
believes that these forward-looking statements are reasonable as
and when made. However, such forward-looking statements are
subject to risks and uncertainties, and actual results may differ
materially from any future results expressed or implied by the
forward-looking statements. Risks and uncertainties include without
limitation the risks inherent in drug development such as those
associated with the initiation, cost, timing, progress and results
of current and future research and development programs,
preclinical and clinical trials, as well as other risk factors
described from time to time in Caribou’s filings with the
Securities and Exchange Commission, including its final prospectus
filed on July 23, 2021. In light of the significant uncertainties
in these forward-looking statements, you should not rely upon
forward-looking statements as predictions of future events. Except
as required by law, Caribou undertakes no obligation to update
publicly any forward-looking statements for any reason.
For more information about Caribou, visit www.cariboubio.com and
follow the company @CaribouBio.
“Caribou Biosciences” and the Caribou logo are registered
trademarks of Caribou Biosciences, Inc.
Caribou Biosciences, Inc. |
Caribou Biosciences, Inc. |
Media
Contact: |
Investor Relations
Contact: |
Greg Kelley |
Elizabeth Wolffe, Ph.D. and
Sylvia Wheeler |
Ogilvy |
Wheelhouse LSA |
gregory.kelley@ogilvy.com |
lwolffe@wheelhouselsa.com |
617-461-4023 |
swheeler@wheelhouselsa.com |
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jul 2023 to Jul 2024